Document:

exv10w4

 

Exhibit 10.4

WEBMETHODS, INC.

2006 OMNIBUS STOCK INCENTIVE PLAN

DEFERRED SHARES AWARD AGREEMENT

(Director Award)

	 	 	 	 	 
	Participant Name:

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	No. of Deferred Shares:

	 	1	 	 
	 

	 	 	 	 

Award Date:

	 	 	 	 	 	 	 
	Vesting Schedule:	 	% Vesting	 	Date of Vesting
	 	 	 	 	 	 	 
	 

	 	 	100	%	 	The earlier of the date of the
first annual meeting of
stockholders of the Company
following the Award Date, the
first annual anniversary of the
Award Date, or a Change in
Control of the Company. For
purposes of this vesting
provision, a “Change in
Control” of the Company shall
mean the earliest to occur of
(i) a merger or consolidation
to which the Company is a party
and which results in, or is
effected in connection with, a
change in ownership of a
majority of the outstanding
shares of voting stock of the
Company, (ii) any sale or
transfer of all or
substantially all of the assets
of the Company to an
unaffiliated third party, or
(iii) the sale by the holders
of a majority of the voting
stock of the Company to an
unaffiliated third party.

          THIS AGREEMENT (the “Deferred Shares Award Agreement” or “Agreement”) is between webMethods,
Inc., Delaware corporation (the “Company”) and the director named above (the “Participant”), and
is delivered under the webMethods, Inc. 2006 Omnibus Stock Incentive Plan, as amended from time to
time (the “Plan”).

WITNESSETH

          WHEREAS, pursuant to the Plan, the Company has granted to the Participant with reference to
services rendered and to be rendered to the Company, effective as of the Award Date, an award of
the right to receive shares of the Company’s common stock delivered on a deferred basis (the
“Award”), upon the terms and conditions set forth herein and in the Plan.

          NOW THEREFORE, in consideration of services rendered and to be rendered by the Participant and
the mutual promises made herein and the mutual benefits to be derived therefrom, the parties agree
as follows:

 

			
	1	 	Subject to adjustment under Section 9 of the
Plan and the terms of this Agreement.

 

 

          1. Defined Terms. Capitalized terms used herein and not otherwise defined herein
shall have the meaning assigned to such terms in the Plan.

          2. Grant. Subject to the terms of this Agreement and the Plan, the Company grants to
the Participant an Award with respect to an aggregate number of Deferred Shares (the “Deferred
Shares”) set forth above.

          3. Account. The Company will establish and maintain a Deferred Shares Account under
the Plan for the Participant. Deferred Shares granted under this Agreement will be credited to the
Participant’s Deferred Shares Account as of the Award Date set forth above.

          4. Vesting. The Award shall vest and become nonforfeitable, with respect to the
applicable portion of the total number of Deferred Shares comprising the Award and Dividend
Equivalent Shares provided in Section 7 of this Agreement (subject to adjustment under Section 9 of
the Plan and herein) in accordance with the vesting schedule set forth above.

          5. Continuance of Service as Director Required. The Vesting Schedule requires
continued service as a Director through the applicable vesting date as a condition to the vesting
of the benefits under this Agreement. Service, even if substantial, other than as a Director of
the Corporation during the vesting period will not entitle the Participant to continued vesting or
avoid or mitigate a termination of rights and benefits upon or following a termination of service
as a Director.

          6. Effect of Termination of Directorship.

               (a) Forfeiture after Certain Events. The Participant’s Deferred Shares shall be
forfeited if such Deferred Shares have not become vested upon the date the Participant’s services
as a Director terminates.

               (b) Termination of Deferred Shares. If any Deferred Shares are forfeited hereunder,
such unvested, forfeited Deferred Shares, without payment of any consideration by the Company,
shall automatically terminate without any other action by the Participant or the Participant’s
Beneficiary, as the case may be.

          7. Dividend and Voting Rights. The Participant shall have no rights as a stockholder
of the Company, no dividend rights (except as expressly provided in this Agreement Plan with
respect to Dividend Equivalent Shares, as defined below) and no voting rights, with respect to the
Deferred Shares and any shares of Common Stock underlying or issuable in respect of such Deferred
Shares until such shares of Common Stock are actually issued to and held of record by the
Participant. The number of Deferred Shares credited to the Participant’s Deferred Shares Account
shall be adjusted from time to time to reflect cash dividends and stock dividends or other changes
in the Common Stock resulting from a change in the Company’s capital structure. Cash dividends on
the Company’s Common Stock shall be credited to the Participant’s Deferred Shares Account in
additional Deferred Shares based on the Fair Market Value of the Common Stock on the dividend
payment date (“Dividend Equivalent Shares”).

          8. Restrictions on Transfer. Except as provided below regarding designation of
Beneficiaries, the Award and the benefits payable by reason of the Award may not

2

 

be alienated, assigned, transferred, pledged or hypothecated by the Participant to any person
or entity at any time in any manner whatsoever.

          9. Payment of Deferred Shares Account.

               (a) Time of Payment. Subject to earlier distribution in accordance with Section 15
hereof or a Hardship Distribution in accordance with Section 9(c), distribution of the
Participant’s vested Deferred Shares Account shall be made as soon as practicable following
Participant’s separation from service as provided in Section 409A(a) of the Code, with distribution
to the Participant who is a “key employee” within the meaning of Section 416(i) of the Code
(determined without regard to paragraph 5 thereof) not made prior to six months following the
Participant’s separation from service (or, if earlier the date of the Participant’s death).

               (b) Method of Distribution. The Participant’s Deferred Shares Account shall be
distributed to the Participant in a single lump sum transfer Common Stock equal the whole number of
vested Deferred Shares and Dividend Equivalent Shares (plus cash representing the value of any
fractional share and Dividend Equivalent Shares payable in cash) as credited to the Participant’s
Deferred Shares Account. In addition, if due to legal, regulatory or other reasons, the Committee
determines that the Dividend Equivalent Shares (or a portion thereof) may not be distributed in
shares of Common Stock, the Company shall make payment of such Dividend Equivalent Shares in cash
in an amount equal to the Fair Market Value of the number of Dividend Equivalent Shares being paid
in cash.

               (c) Hardship Distributions. Prior to the time the Participant’s Deferred Shares Account
becomes payable, the Committee, in its sole discretion, may elect to distribute all or a portion of
the number of whole Deferred Shares (plus cash representing the value of any fractional share and
Dividend Equivalent Shares payable in cash) credited to such Deferred Shares Account in the event
such Participant requests a distribution due to severe financial hardship. Severe financial
hardship shall be deemed to exist in the event the Committee determines that the Participant needs
a distribution to meet immediate and heavy financial needs resulting from a sudden or unexpected
illness or accident of the Participant or a member of the Participant’s family, loss of the
Participant’s property due to casualty or other similar extraordinary and unforeseeable
circumstances arising as a result of events beyond the control of the Participant. No distribution
shall be made due to a severe financial hardship under this paragraph, to the extent such hardship
may be relieved through reimbursement or compensation from insurance or otherwise, by liquidation
of the Participant’s assets, to the extent liquidation of such assets would not by itself cause
severe hardship, or by cessation of deferrals. A distribution based on financial hardship shall not
exceed the smaller of (i) the amount of cash and the number of whole Deferred Shares (plus cash
representing the value of any fractional share and Dividend Equivalent Shares payable in cash)
credited to the Participant’s Deferred Shares Account or (ii) the number of whole Deferred Shares
credited to the Participant’s Deferred Shares Account with a Fair Market Value (determined as of
the date of distribution) equal to the amount needed to meet the financial hardship. This paragraph
shall be applied in conformity with the “unforeseeable emergency” rules of Section 409A(a)(2) of
the Code.

3

 

               (d) Designation of Beneficiary. Upon the death of the Participant prior to the
distribution of his or her Deferred Shares Account, such vested Deferred Shares Account shall be
paid to the Beneficiary designated by the Participant in a single lump sum transfer of shares of
Common Stock (plus cash representing the value of any fractional share and Dividend Equivalent
Shares payable in cash) as provided in Section 9(b) hereof, as soon as practicable after the
Participants’ death. If there is no designated Beneficiary or no designated Beneficiary surviving
at the Participant’s death, payment of the Participant’s Deferred Shares Account shall be made to
the Participant’s estate.

               (e) Incapacity Of Recipient. In the event that the Participant or Beneficiary is
declared incompetent and a guardian, conservator or other person legally charged with the care of
his or her person or of his or her estate is appointed, any benefits under this Agreement to which
such Participant or Beneficiary is entitled shall be paid to such guardian, conservator or other
person legally charged with the care of his person or his estate. Except as provided hereinabove,
when the Committee, in its sole discretion, determines that the Participant or Beneficiary is
unable to manage his or her financial affairs, the Committee may, but shall not be required to,
direct the Company to make distribution(s) to any one or more of the spouse, lineal ascendants or
descendants or other closest living relatives of such Participant or Beneficiary who demonstrates
to the satisfaction of the Committee the propriety of making such distribution(s). Any payment made
under this Section 9(e) shall be in complete discharge of any liability of the Company for such
payment. The Committee shall not be required to see to the application of any such distribution
made to any person.

          10. Adjustments Upon Specified Events. Upon the occurrence of certain events relating
to the Company’s stock contemplated by Section 9 of the Plan, the Board shall make adjustments as
it deems appropriate in the number and kind of securities or other consideration that may become
payable with respect to the Award in accordance with Section 9 of the Plan.

          11. Notices. Any notice to be given under the terms of this Agreement shall be in
writing and addressed to the Company at its principal office, to the attention of the General
Counsel, and to the Participant at his or her last address of record, or at such other address as
either party may hereafter designate in writing to the other for the purposes of notices in respect
of Deferred Shares.

          13. Limitation on Participant’s Rights; Unfunded Obligation. This Agreement confers
no rights or interests other than as herein provided. This Agreement creates only a contractual
obligation on the part of the Company as to amounts payable and shall not be construed as creating
a trust or fiduciary relationship between the Company, the Committee, and the Participant. The
Participant and his or her Beneficiaries shall have no legal or equitable rights, claims, or
interest in any specific property or assets of the Company. No assets of the Company shall be held
under any trust, or held in any way as collateral security for the fulfilling of the obligations of
the Company under this Agreement. Any and all of the Company’s assets shall be, and remain, the
general unpledged, unrestricted assets of the Company. The Company’s obligation under this
Agreement shall be merely that of an unfunded and

4

 

unsecured promise of the Company to pay benefits in the future, and the rights of the
Participant and Beneficiaries shall be no greater than those of unsecured general creditors.

          14. Amendment of this Agreement . The Board and Committee reserve the right
to amend the terms of this Agreement as it deems appropriate or necessary to comply with Section
409A of the Code.

          15. Binding Upon Successors. The terms of this Agreement shall be binding upon and
inure to the benefit of the Company, its successors and assigns and the Participant and his or her
heirs, executors, administrators and legal representatives. In the event of (a) a merger or
consolidation of the Company with or into any other corporation that qualifies as a “change in
control event” under the provisions of Section 409A(a)(2)(A)(v) of the Code, or (b) the sale or
transfer of substantially all of the assets of the Company that qualifies as a “change in control
event” under the provisions of Section 409A(a)(2)(A)(v) of the Code, then, either (i) the deferred
compensation plan created by this Agreement shall be terminated and amounts allocated to
Participant’s Deferred Share Award Accounts distributed to the Participant or (ii) the successor
corporation resulting from the merger or consolidation, or the transferee of such assets, as the
case may be, shall, as a condition to the consummation of the merger, consolidation or transfer,
assume the obligations of the Company hereunder and shall be substituted for the Company hereunder.
Any such termination or assumption of the obligations under this Agreement shall be made in
accordance with Section 409A of the Code and applicable guidance thereunder.

          16. Choice of Law. The constructive interpretation, performance and enforcement of
this Award Agreement and the Award shall be governed by the laws of the State of Delaware.

5

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. By the Participant’s execution of this Agreement, the Participant agrees to the terms and
conditions of this Agreement and of the Plan.

	 	 	 	 	 	 	 
	webMethods, Inc.

	 	 	 	PARTICIPANT
	 	 
	(a Delaware corporation)
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	By:

	 	 	 	(Signature)	 	 
	Its:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(Print Name)	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(Address)	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	(City, State, Zip Code)	 	 

6

 

WEBMETHODS, INC.

2006 OMNIBUS STOCK INCENTIVE PLAN

DEFERRED SHARES AWARD

BENEFICIARY DESIGNATION

Please complete this form to designate a beneficiary to receive your vested Deferred Share 
Award in the event of your death before payment.

Award Date to which the Form Applies

     I hereby designate                      as my primary Beneficiary and
                                         as my contingent Beneficiary(ies) to receive my
vested Deferred Share Award any amounts payable under the Plan in the event of my death.

	 	 	 	 	 	 	 
	 

	 	PARTICIPANT
	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 
	 	 	 	 
	 

	 	(Signature)
	 	(Date)	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	(Print Name)exv10w12

 

Exhibit 10.12

CONFIDENTIAL TREATMENT REQUESTED

CORPORATE FORMATION AGREEMENT

     This Corporate Formation Agreement (this “Agreement”) is made and entered into as of December
26, 2003 (the “Effective Date”) by and between Asthmatx, Inc. (“Asthmatx”), a California
corporation, and Broncus Technologies, Inc., a California corporation (“Broncus”).

RECITALS

     A. Broncus has caused Asthmatx to be incorporated and now wishes to contribute to Asthmatx
cash and certain assets, agreements and obligations of Broncus relating to Broncus’ Alair Asthma
Treatment System business (the “Alair Business”) in exchange for the Asthmatx Shares (as defined
herein) and other consideration described herein.

     B. It is contemplated that, prior to December 31, 2003, Broncus will distribute the Asthmatx
Shares (as defined herein) on a pro rata basis as a dividend to its shareholders (such distribution
and dividend being referred to herein as the “Spin-off”). Asthmatx has been provided with a copy
of an Information Statement prepared by Broncus which describes the Spin-off.

     C. Broncus has previously issued certain warrants to purchase shares of its Common Stock that
are now outstanding and listed in Exhibit A attached hereto (the “Broncus Warrants”), and,
after the occurrence of the Spin-off, Broncus will be required by the terms of the Broncus Warrants
to provide that the Warrant holders will receive shares of Asthmatx’s Common Stock upon exercise of
their Broncus Warrants. In consideration of the agreements of Broncus contained herein, Asthmatx
is willing to agree to issue shares of its Common Stock as provided herein upon the exercise of
Broncus Warrants in order to enable Broncus to satisfy its obligations under the Broncus Warrants.

     D. In consideration of Broncus’ agreements herein, Asthmatx is also willing to agree to grant
options to purchase shares of its Common Stock to holders of Broncus stock options and to employees
of Broncus who will become employees of Asthmatx as provided herein.

     E. The parties also desire to provide, in connection with the formation of Asthmatx, that they
will enter into certain agreements between themselves as provided herein.

AGREEMENT

     NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants
hereinafter set forth, Asthmatx and Broncus hereby agree as follows:

     1. Contribution and Transfer of Assets; Issuance of Asthmatx Shares.

          1.1 Contribution and Transfer of Assets. Broncus hereby contributes, assigns,
transfers, conveys and delivers to Asthmatx, as of the Effective Date, all of Broncus’ right, title
and interest in, to or under all of the assets and properties identified in the following
subparagraphs of this Section 1.1 (collectively, the “Assigned Assets”):

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

 

 

               (a) cash in the amount equal to forty percent (40%) of the cash held by Broncus on the
Effective Date (which amount Broncus and Asthmatx agree and acknowledge will take into account
Broncus’ payment of those accounts payable paid on or before the Effective Date and which amount
Broncus and Asthamtx estimate will be approximately $2,150,000);

               (b) the tangible personal property assets of Broncus that are identified on Schedule
1.1(b) attached hereto;

               (c) the contracts and agreements that are identified on Schedule 1.1(c) attached
hereto (the “Assigned Contracts”);

               (d) the patents and patent applications specifically listed on Schedule 1.1(d)
attached hereto, all worldwide rights to the inventions described therein, and all rights to
enforce such patents (and any patents that may be issued on any such patent applications) and all
causes of action and rights of recovery for past infringement of such patents, patent applications
and inventions described therein (collectively, the “Assigned Patent Rights”);

               (e) the trademarks and trademark registrations that are identified on Schedule 1.1(e)
attached hereto, and all applications therefor, trade names and rights in trade dress and packaging
associated therewith (collectively, the “Assigned Trademark Rights”);

               (f) the intangible assets, technologies, properties and rights of Broncus that are associated
exclusively with the Alair Asthma Treatment System (including the Alair Controller Software, the
Alair Product Specification, training materials related to the Alair Program, publications
regarding the Alair procedure and all trade dress/design features for the Alair System), including
all patent rights associated therewith, copyrights, copyright registrations and applications
therefor, trade secrets, know-how and other intellectual property rights recognized by the law of
any applicable jurisdiction (collectively, “Intellectual Property Rights”) therein and thereto, all
rights to enforce such Intellectual Property Rights, and all causes of action and rights of
recovery for past infringement of such Intellectual Property Rights; and

               (g) the books and records of Broncus which relate to the assets described in clauses (a)
through (f) above and do not relate to the Excluded Assets (provided that Broncus shall be
entitled to retain a copy of such books and records).

Notwithstanding the foregoing, the Assigned Assets shall not in any event include any of
the assets, properties and rights owned or held by Broncus that are not expressly identified in the
preceding subparagraphs of this Section 1.1 (collectively, the “Excluded Assets”), such as, by way
of illustration and not limitation, assets, properties, agreements, contracts, technologies and
Intellectual Property Rights associated with Broncus’ Exhale emphysema treatment system and not
expressly defined as Assigned Assets herein.

          1.2 Issuance of Asthmatx Shares and Grant of Asthmatx Options. In partial
consideration for Broncus’ contribution and transfer to Asthmatx of the Assigned Assets and the
commitments of Broncus contained in this Agreement, and such other good and valuable

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 2 -

 

consideration, the receipt and sufficiency of which are hereby acknowledged, Asthmatx hereby
agrees with Broncus as follows:

               (a) Issuance of Asthmatx Shares. Asthmatx hereby agrees with Broncus to, and hereby
does, issue and sell to Broncus, and Broncus hereby acquires from Asthmatx, an aggregate total of
(i) 3,883,541 shares of Asthmatx’s Common Stock, (ii) 2,612,500 shares of Asthmatx’s Series A-1
Preferred Stock, (iii) 2,090,000 shares of Asthmatx’s Series A-2 Preferred Stock, (iv) 1,045,000
shares of Asthmatx’s Series A-3 Preferred Stock, (v) 4,280,000 shares of Asthmatx’s Series B
Preferred Stock, (vi) 9,619,528 shares of Asthmatx’s Series C Preferred Stock, and (vii) 9,271,159
shares of Asthmatx’s Series D Preferred Stock (all such shares of Asthmatx Common Stock and
Asthmatx Preferred Stock being collectively referred to herein as the “Asthmatx Shares”).

               (b) Issuance of Common Shares Upon Exercise of Broncus Warrants. In addition to the
issuance to Broncus of the Asthmatx Shares pursuant to Section 1.1(a) above, Asthmatx hereby agrees
with Broncus that, within a reasonable time after each exercise of a Broncus Warrant that occurs
after the date of the Spin-off (a “Broncus Warrant Exercise”), Asthmatx shall issue to the holder
of such Broncus Warrant who has exercised such Broncus Warrant one (1) share of Asthmatx Common
Stock, as presently constituted (the “Issue Number”) for each share of Broncus Common Stock that is
issued to and received by the holder of such Broncus Warrant as a result of such Broncus Warrant
Exercise (with the Issue Number to be equitably and proportionally adjusted to account for and
reflect any stock splits, stock dividends, reverse stock splits or the like occurring after the
date of the Spin-off and affecting the number of outstanding shares of the Common Stock of either
Asthmatx or Broncus); provided, however, that Asthmatx shall not be obligated to
issue its Common Stock under this Section 1.2(b) with respect to a Broncus Warrant Exercise unless
and until Broncus has provided Asthmatx with written notice of such Broncus Warrant Exercise, which
notice shall include (i) the name and address of the holder of the Broncus Warrant exercised in
connection with such Broncus Warrant Exercise; (ii) the name and address of the person(s) in whose
name the shares of Asthmatx’s Common Stock issuable hereunder in respect of such Broncus Warrant
Exercise are to be registered; and (iii) a statement of the number of Broncus shares purchased in
connection with such Broncus Warrant Exercise, and Broncus’ computation of the number of shares of
Asthmatx’s Common Stock then issuable in respect of such Broncus Warrant Exercise in accordance
with this Section 1.2(b).

               (c) Grant of Asthmatx Stock Options to Broncus Optionees. Effective at a time prior
to the time the Spin-off takes effect and during which Asthmatx is a subsidiary of Broncus,
Asthmatx shall grant to each Broncus Optionee (as defined below), with respect to each outstanding
option to purchase Broncus Common Stock held by such Broncus Optionee (a “Broncus Option”), an
option to purchase shares of Asthmatx Common Stock (an “Asthmatx Option”) on the following basis
and terms, except as otherwise noted below:

                    (i) the number of shares of Asthmatx Common Stock subject to each Asthmatx Option granted to a
Broncus Optionee under this Section 1.2(c) with respect to a Broncus Option will (except as
may be otherwise specified in Schedule 1.2(c) attached hereto) be equal to the number of
shares of Broncus Common Stock with respect to which such Broncus Option was vested and exercisable
on the date such Asthmatx Option is granted (or, if exercise

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 3 -

 

of such Broncus Option was not subject to a vesting condition, the number of shares of Broncus
Common Stock subject to such Broncus Option that, on such date of grant, is not subject to
repurchase by Broncus at its original issue price upon termination of the Broncus Optionee’s
services);

                    (ii) the exercise price per share of such Asthmatx Option shall be a price per share of
Asthmatx Common Stock that is forty percent (40%) of the exercise price per share at which shares
of Broncus Common Stock are purchasable under such Broncus Option (computed before the effect of
any modification or adjustment of such Broncus Option made in connection with the Spin-off);

                    (iii) such Asthmatx Option shall continue to be exercisable by such Broncus Optionee for so
long as such Broncus Optionee continues to be employed by, or provide services to, Broncus or a
parent or subsidiary of Broncus (as those terms are defined in Broncus’ option plans) but in no
event beyond the scheduled expiration date of the Broncus Option with respect to which such
Asthmatx Option is granted; and

                    (iv) other terms not described in the foregoing clauses (i) through (iii) that are
substantially the same as the terms of the Broncus Option with respect to which such Asthmatx
Option is granted;

provided, however, that solely for purposes of determining the number of shares of
Asthmatx Common Stock subject to an Asthmatx Option granted to a Broncus Optionee with respect to a
Broncus Option that has not vested on the date of the Spin-off due to probationary “cliff” vesting
provisions (“Cliff Vesting”), such Broncus Option will be deemed to have been vested as of the date
of the Spin-off as to that portion of the Broncus Option subject to Cliff Vesting that is
proportional to the number of months elapsed between the beginning of the Cliff Vesting period and
the date of the Spin-off, but such Asthmatx Option will not actually become vested or exercisable
until the Broncus Optionee has provided the number of months of service to Broncus required to
satisfy the original Cliff Vesting provision under such Broncus Option. For purposes of this
Section 1.2, the term “Broncus Optionee” means an individual (other than an individual who entirely
terminates his or her employment with Broncus in order to become a full-time employee of Asthmatx)
who on the date of the Spin-off holds at least one outstanding option to purchase shares of Broncus
Common Stock.

               (d) Grant of Asthmatx Stock Options to Transferring Optionee. On or before the time
the Spin-off takes effect, Asthmatx shall grant to each Broncus employee who has become an employee
of Asthmatx on or before the date the Spin-off takes effect (each a “Transferring Optionee”), with
respect to each Broncus Option held by such Transferring Optionee (a “Broncus Option”), an Asthmatx
Option on the following basis and terms, except as otherwise noted below:

                    (i) the number of shares of Asthmatx Common Stock subject to each Asthmatx Option granted to a
Transferring Optionee under this Section 1.2(d) with respect to a Broncus Option held by such
Transferring Optionee will (except as may be otherwise specified in Schedule 1.2(d)
attached hereto) be equal to the total number of shares of Broncus Common Stock subject to such
Broncus Option, whether or not vested (computed before the

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 4 -

 

effect of any modification or adjustment of such Broncus Option made in connection with the
Spin-off);

                    (ii) the exercise price per share of each such Asthmatx Option shall be a price per share of
Asthmatx Common Stock that is forty percent (40%) of the exercise price per share at which shares
of Broncus Common Stock are purchasable under such Broncus Option (computed before the effect of
any modification or adjustment of such Broncus Option made in connection with the Spin-off);

                    (iii) each Asthmatx Option granted to such Continuing Broncus Optionee (A) shall be vested on
the date it is granted to the same extent that the Broncus Option with respect to which it was
granted was vested on such date, and (B) shall vest and become exercisable on the same terms and
vesting schedule as the Broncus Option with respect to which it was granted, except that, for
purposes of vesting, all applicable references to Broncus in such Broncus Option shall be
references to Asthmatx in such Asthmatx Option;

                    (iv) each such Asthmatx Option shall continue to be exercisable by such Transferring Optionee
for so long as such Transferring Optionee continues to be employed by, or provide services to,
Asthmatx or a Parent or Subsidiary of Asthmatx (as those terms are defined in Asthmatx’s option
plan) but in no event beyond the scheduled expiration date of the Broncus Option with respect to
which such Asthmatx Option is granted; and

                    (v) other terms not described in the foregoing clauses (i) through (iv) that are substantially
the same as the terms of the Broncus Option with respect to which such Asthmatx Option is granted.

     2. Assumption of Obligations and Liabilities .

          2.1 Certain Defined Terms. As used herein, the following terms shall have the following
meanings:

               (a) “Alair” means the Alair Asthma Treatment System which was originally developed by Broncus
and which has been contributed and assigned by Broncus to Asthmatx pursuant to this Agreement.

               (b) “Alair Business” shall have the meaning given to that term in Recital A of this Agreement
and includes, without limitation, the business of developing, testing, marketing, selling and
otherwise commercially exploiting Alair and any associated services.

               (c) “Exhale” means Broncus’ Exhale Airway Bypass System, which is used to treat emphysema in
humans and which is owned and retained by Broncus.

               (d) “Exhale Business” means Broncus’ business of developing, testing, marketing, selling and
otherwise commercially exploiting Exhale and any associated services.

               (e) “Liabilities” means, collectively, any and all liabilities, losses, claims, debts, duties,
obligations (including but not limited to contractual obligations), expenses,

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 5 -

 

claims, deficiencies or guaranties of any type, whether accrued, absolute, contingent,
matured, unmatured or otherwise.

               (f) “Loss” means, collectively, all Liabilities, loss, damages, expense, cost, fines, fees,
penalties, obligations or injuries, including without limitation those resulting from any and all
claims, actions, suits, demands, assessments, investigations, judgments, awards, arbitrations or
other proceedings, together with reasonable costs and expenses including the reasonable attorneys’
fees and other legal costs and expenses relating thereto.

          2.2 Assumption of Liabilities by Asthmatx. Except to the extent that Asthmatx is
expressly entitled to be indemnified for any of such Liabilities by Broncus pursuant to the
provisions of the Indemnification Agreement (as that term is defined in Section 2.3 below),
Asthmatx hereby assumes and agrees to faithfully and timely pay, perform, fulfill and satisfy in
full all of the following Liabilities (collectively, the “Assumed Liabilities”):

               (a) any and all Liabilities, to the extent that such Liabilities relate to, arise out of or
result from the conduct or operation of the Alair Business by any person or entity (including but
not limited to Broncus, Asthmatx and/or by any other party or parties) at any time, whether before,
on or after the Effective Date; and

               (b) any Liability to the extent it relates to, arises out of, or results from, any of the
Assigned Assets (including without limitation any of the Assigned Contracts) whether such Liability
arises before, on or after the Effective Date.

          2.3 Indemnification Agreement. The parties mutually agree, as soon as reasonably
practicable, to enter into a separate written agreement between themselves (such agreement being
referred to herein as the “Indemnification Agreement”). The Indemnification Agreement will
provide for and address the following matters: (a) the terms and conditions upon which Asthmatx
will undertake to use good faith efforts to obtain certain liability insurance relating to the
Alair Business; (b) the terms and conditions upon which Asthmatx will indemnify Broncus for Loss
related to the Alair Business (including the Assumed Liabilities); (c) the terms and conditions
upon which Broncus will indemnify Asthmatx for Loss related to the Exhale Business; and (d) the
terms and conditions upon which the parties will have access to and may obtain coverage under,
certain insurance policies held by Broncus providing coverage for certain third-party claims
arising from the treatment of individuals with Alair prior to the Effective Date (which may include
provisions pursuant to which Broncus may, from the proceeds of such insurance policies, provide
certain limited indemnification to Asthmatx with respect to such third-party claims).

     3. Further Assurances. The parties agree to execute such further documents
and instruments and to take such further actions as may be reasonably necessary to carry out the
purposes and intent of this Agreement. Broncus further agrees, promptly upon request of Asthmatx,
or any of its successors or assigns, to, at Asthmatx’s expense, to execute, deliver and/or assist
in the filing of (i) recordable patent assignments for each patent or patent application included
in the Assigned Patent Rights, (ii) recordable trademark assignments for each trademark, trademark
application or similar right included in the Assigned Trademark Rights, and (iii) any power of
attorney, assignment, application for copyright, patent or other

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 6 -

 

intellectual property right protection, or any other papers which may be necessary or
desirable to fully secure to Asthmatx, its successors and assigns, all right, title and interest in
and to each of the Assigned Assets. In addition, Broncus agrees never to assert any claims, rights
or moral rights in or to any of the Assigned Assets, except such rights, if any, as Broncus may
hold under a separate written agreement executed by Broncus and Asthmatx.

     4. Representations and Warranties of Broncus. Broncus represents and
warrants to Asthmatx that, as of the Effective Date:

          4.1 Corporate Organization. Broncus is a corporation duly organized, validly existing
and in good standing under the laws of the State of California, and has the corporate power and
authority to enter into and perform its obligations under this Agreement.

          4.2 Authority. The execution, delivery and performance of this Agreement, and the
performance by Broncus of the transactions contemplated hereby, have been duly and validly approved
and authorized by all necessary action of Broncus’ Board of Directors. This Agreement is the valid
and binding obligation of Broncus, enforceable in accordance with its terms, except as to the
effect, if any, of (i) applicable bankruptcy, insolvency, reorganization or other laws of general
application relating to or affecting the enforcement of creditors’ rights generally and (ii) rules
of law governing specific performance, injunctive relief and other equitable remedies.

          4.3 No Conflict. Neither the execution and delivery of this Agreement, nor the
consummation of the transactions contemplated hereby, will conflict with or violate any provision
of the Articles of Incorporation or Bylaws of Broncus.

          4.4 Securities Law Matters. Broncus is not acquiring the Asthmatx Shares with a view
to, or for sale in connection with, any unlawful distribution of the Asthmatx Shares within the
meaning of the Securities Act of 1933, as amended (the “Securities Act”). Broncus has a
preexisting business relationship with Asthmatx and/or certain of its officers and/or directors of
a nature and duration sufficient to make Broncus aware of the character, business acumen and
general business and financial circumstances of Asthmatx and/or such officers and directors. By
reason of Broncus’ business and financial experience, Broncus is capable of evaluating the merits
and risks of this investment, has the ability to protect Broncus’ own interests in this transaction
and is financially capable of bearing a total loss of this investment.

          4.5 Assigned Assets. To Broncus’ knowledge, (a) Broncus owns, and can grant exclusive
right, title and interest in and to, each of the Assigned Assets, (b) none of the Assigned Assets
are presently subject to any dispute, claim, prior license or other agreement, assignment or rights
of any third party, or any other rights that might interfere with Asthmatx’s use, or exercise of
ownership of, any Assigned Assets, nor is Broncus aware of any claims by any third party to any
rights of any kind in or to any of the Assigned Assets, and (c) none of the Assigned Assets are
subject to any lien, pledge, mortgage, security interest or other encumbrance of any sort (other
than such Liabilities as are assumed by Asthmatx pursuant to Section 2 of this Agreement and other
than any lien that would have no material affect on Asthmatx’s ability to use or transfer an
Assigned Asset).

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 7 -

 

     5. ACKNOWLEDGMENT AND AGREEMENT BY BRONCUS AND ASTHMTAX REGARDING SPIN-OFF.
Broncus and Asthmatx acknowledge and agree that (i) the Asthmatx Shares are not being registered
with the Securities and Exchange Commission under the Securities Act or being qualified under the
California Corporate Securities Law of 1968, as amended, or other applicable state securities laws,
but instead are being issued under exemptions from the registration and qualification requirements
of such securities laws which impose certain restrictions on the subsequent sale, transfer or other
disposition the Asthmatx Shares by Broncus and Broncus’ shareholders, and (ii) the stock
certificates representing the Asthmatx Shares will bear restrictive legends as set forth in Section
6.1 to enable Asthmatx to enforce the aforementioned transfer restrictions and such transfer
restrictions will be noted in Asthmatx’s stock transfer books. Broncus and Asthmatx further
acknowledge and agree that the aforementioned transfer restrictions will apply to the Asthmatx
Shares (and will continue to apply to the Asthmatx Shares in the hands of Broncus’ shareholders who
receive them in the Spin-off).

     6. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS.

          6.1 Legends. Broncus understands and agrees that Asthmatx will place the legends set
forth below or similar legends on any stock certificate(s) evidencing the Asthmatx Shares, together
with any other legends that may be required by state or federal securities laws, Asthmatx’s
Articles of Incorporation or Bylaws, any other applicable agreement between Broncus, Asthmatx
and/or any third parties:

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY
NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD
BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT
FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT
THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A 180 DAY MARKET STANDOFF
RESTRICTION AS SET FORTH IN A CERTAIN AGREEMENT BETWEEN THE ISSUER AND THE
ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICE OF THE ISSUER. AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT
BE TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF A PUBLIC OFFERING OF THE
COMMON STOCK OF THE ISSUER HEREOF. SUCH RESTRICTION IS BINDING ON TRANSFEREES OF
THESE SHARES.

          6.2 Stop-Transfer Instructions. Broncus agrees that, to ensure compliance with
the restrictions imposed by this Agreement, Asthmatx may issue appropriate “stop-transfer”
instructions to its transfer agent, if any, and if Asthmatx transfers its own securities, it may
make appropriate notations to the same effect in its own records.

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 8 -

 

          6.3 Refusal to Transfer. Asthmatx will not be required (a) to transfer on its books
any Asthmatx Shares that have been sold or otherwise transferred in violation of any of the
provisions of this Agreement or (b) to treat as owner of such Asthmatx Shares, or to accord the
right to vote or pay dividends, to any purchaser or other transferee to whom such Asthmatx Shares
have been so transferred; provided, however, that Broncus and Asthmatx acknowledge
and agree that the transfer, distribution and dividend of the Asthmatx Shares to Broncus’
shareholders in connection with the Spin-off shall not constitute a transfer in violation of any of
the provisions of this Agreement and this Section 6.3 shall not apply to any such transfer.

          6.4 Market Stand Off Agreement. Broncus agrees, in connection with any registration
of Asthmatx’s securities under the Securities Act that, upon the request of Asthmatx or the
underwriters managing any registered public offering of Asthmatx’s securities, Broncus will not
sell or otherwise dispose of any Asthmatx Shares without the prior written consent of Asthmatx or
such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty
(180) days) after the effective date of such registration requested by such managing underwriters
and subject to all restrictions as Asthmatx or the managing underwriters may specify for
employee-shareholders generally. Broncus further agrees to enter into any agreement reasonably
required by the underwriters to implement the foregoing.

     7. CERTAIN AGREEMENTS.

          7.1 License and Manufacturing Agreements. To assist Asthmatx in commencing business
as a separate entity following the Spin-off and to afford each other certain assurances regarding
each party’s ability to use and practice certain intellectual property rights, the parties agree
that, concurrently with the Spin-off, they shall: (a) enter into a License Agreement having the
principal terms summarized in the Term Sheet attached as Exhibit B hereto, under which each
party would grant the other a license to use certain of its intellectual property rights within a
defined field of use (the “Cross-License Agreement”); and (b) a Manufacturing Service Agreement in
substantially the form attached hereto as Exhibit C (the “Manufacturing Agreement”),
pursuant to which Broncus would agree to manufacture certain devices for Asthmatx in exchange for
cash charges. The definitive forms of the Cross-License Agreement and the Manufacturing Agreement
executed by the parties shall be the sole and exclusive agreement and understanding of the parties
with regard to the subject matter of such agreements.

     8. GENERAL PROVISIONS .

          8.1 Governing Law. This Agreement will be governed by and construed in accordance
with the laws of the State of California, without giving effect to that body of laws pertaining to
conflict of laws.

          8.2 Further Assurances. The parties agree to execute such further documents and
instruments and to take such further actions as may be reasonably necessary to carry out the
purposes and intent of this Agreement.

          8.3 Counterparts; Facsimile Signatures. This Agreement may be executed in any number
of counterparts, each of which when so executed and delivered will be deemed an

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 9 -

 

original, and all of which together shall constitute one and the same agreement. This
Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature
will be deemed to have the same effect as if the original signature had been delivered to the other
party.

          8.4 Severability. If any provision of this Agreement is determined by any court or
arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such
provision will be enforced to the maximum extent possible given the intent of the parties hereto.
If such clause or provision cannot be so enforced, then such provision shall be stricken from this
Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or
unenforceable clause or provision had (to the extent not enforceable) never been contained in this
Agreement.

          8.5 Notices. Any and all notices required or permitted to be given to a party
pursuant to the provisions of this Agreement will be in writing and will be effective and deemed to
provide such party sufficient notice under this Agreement on the earliest of the following: (i) at
the time of personal delivery, if delivery is in person; (ii) one (1) business day after deposit
with an express overnight courier for United States deliveries, or two (2) business days after such
deposit for deliveries outside of the United States, with proof of delivery from the courier
requested; or (iii) three (3) business days after deposit in the United States mail by certified
mail (return receipt requested) for United States deliveries. All notices for delivery outside the
United States will be sent by express courier. All notices not delivered personally will be sent
with postage and/or other charges prepaid and properly addressed to the party to be notified at the
address set forth on the signature page to this Agreement (or at such other address as the party to
be notified may have designated to the other party by one of the indicated means of notice herein).

          8.6 Amendment and Waivers. This Agreement may not be altered or amended except by an
instrument in writing executed by Broncus and Asthmatx. No rights of a party under this Agreement
may be waived, except by an instrument in writing executed by such party. No waiver of any terms,
provision or condition of or failure to exercise or delay in exercising any rights or remedies
under this Agreement, in any one or more instances shall be deemed to be, or construed as, a
further or continuing waiver of any such term, provision, condition, right or remedy or as a waiver
of any other term, provision or condition of this Agreement.

          8.7 Entire Agreement. This Agreement and the documents referred to herein and
exhibits hereto constitute the entire agreement and understanding of the parties with respect to
the subject matter of this Agreement, and supersede all prior understandings and agreements,
whether oral or written, between or among the parties hereto with respect to the specific subject
matter hereof.

[Signature page follows]

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

- 10 -

 

     In Witness Whereof, the parties hereto have executed this Corporate Formation
Agreement as of the Effective Date set forth in the first paragraph hereof.

	 	 	 	 	 
	ASTHMATX, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Glen French	 	 
	 

	 	 

Glen French, President
	 	 
	 
	 	 	 	 
	Address:

	 	1340 Space Park Way	 	 
	 

	 	Mountain View, CA 94043	 	 

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

 

 

     In Witness Whereof, the parties hereto have executed this Corporate Formation
Agreement as of the Effective Date set forth in the first paragraph hereof.

	 	 	 	 	 
	BRONCUS TECHNOLOGIES, INC.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Cary Cole	 	 
	 

	 	 

Cary Cole, President
	 	 
	 
	 	 	 	 
	Address:

	 	1400 North Shoreline Blvd, Suite A8	 	 
	 

	 	Mountain View, CA 94043	 	 

*****
Certain portions of this exhibit have been omitted and confidential
treatment has been requested for these omitted portions pursuant to
an application for confidential treatment sent to the Securities and
Exchange Commission.

 

 

Exhibit A

Broncus Warrants

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Number of Shares of Broncus
	 	 	Warrant	 	 	 	 	 	 	 	 	 	Common Stock Issuable Upon
	Broncus Warrant Holder	 	Number	 	Issue Date	 	Expiration Date	 	Exercise in Full
	*****
	 	CS-01	 	 	3/20/1998	 	 	 	3/19/2008	 	 	 	20,000	 
	*****
	 	CS-02	 	 	1/24/2000	 	 	1/24/2005 or trans or IPO	 	 	48,077	 
	*****
	 	CS-03	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	519,143	 
	*****
	 	CS-04	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	58,118	 
	*****
	 	CS-05	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	2,325	 
	*****
	 	CS-06	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	37,082	 
	*****
	 	CS-07	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	371	 
	*****
	 	CS-08	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	1,854	 
	*****
	 	CS-09	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	2,225	 
	*****
	 	CS-10	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	2,225	 
	*****
	 	CS-11	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	27,440	 
	*****
	 	CS-12	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	37,082	 
	*****
	 	CS-13	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	46,352	 
	*****
	 	CS-14	 	 	2/13/2002	 	 	2/13/2005 or IPO	 	 	6,675	 

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

Schedule 1.1(b)

Tangible Personal Property

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Item	 	Model Number	 	Serial Number	 	QTY	 	Price
	Kelly Shriner’s computer

	 	Compaq Evo (P4 1800) Desktop
	 	W233KN8ZB374
	 	 	1	 	 	$	1,500	 
	Gary Kaplan’s computer

	 	Dell Optiplex GX110 (866) Desktop
	 	127-646-228-17 / 5V3Q601
	 	 	1	 	 	$	1,500	 
	Narinder Shargill’s computer

	 	Dell Latitude L400 (???) Laptop
	 	19526848885 / 8YXS511
	 	 	1	 	 	$	2,000	 
	Debbie Brown’s computer

	 	Compaq Evo (P4 1500) Desktop
	 	6X1CJYFZJ101
	 	 	1	 	 	$	1,500	 
	Bill Wizeman’s computer

	 	Compaq Evo (P4 1500) Desktop
	 	6X1CJYFZJ0ZY
	 	 	1	 	 	$	1,500	 
	Steve Fermi’s computer

	 	Dell Optiplex GX100 (500) Desktop
	 	286-394-149-55 / D5N620B
	 	 	1	 	 	$	1,500	 
	Glen French’s computer

	 	Compaq Evo N610c (?????) Laptop
	 	 	 	 	1	 	 	$	2,000	 
	Glen French — Fax

	 	HP 720
	 	 	 	 	1	 	 	$	250	 
	Chris Danek — computer

	 	Dell Dimension XPS R350 Desktop
	 	273-964-89 / GB79L
	 	 	1	 	 	$	1,500	 
	Marilyn Foust — computer

	 	Dell Dimension XPS R350 Desktop
	 	286-382-89 / H1TG1
	 	 	1	 	 	$	1,500	 
	Barrie Weeks — computer

	 	Compaq Evo (P4 1700) Desktop
	 	6X24JYFZN05D
	 	 	1	 	 	$	1,500	 
	Grant Laptop

	 	Compaq Evo N610c (P4-2400) Laptop
	 	7E35KT8ZD18Y
	 	 	1	 	 	$	2,800	 
	glen’s old laptop

	 	Compaq Evo N400c (P3 700) Laptop
	 	1J16JMWZV62J
	 	 	1	 	 	$	2,000	 
	glen’s old desktop

	 	Compaq Deskpro EN (P3 866) Desktop
	 	6125FR4ZB271
	 	 	1	 	 	$	1,500	 
	trudy’s old laptop

	 	Compaq Evo N800c (P4 2000) Laptop
	 	9X2AKQFZJ08F
	 	 	1	 	 	$	2,000	 
	Copier (36 monthly payments
of $287 starting December
2003)

	 	Imagistics DL37
	 	2100049
	 	 	1	 	 	$	9,000	 
	Task Chairs

	 	Gray Office Master Chairs
	 	 	 	 	8	 	 	$	200	 
	File cabinets

	 	Hon 4 drawer letter size vertical
	 	 	 	 	11	 	 	$	100	 
	Microscope

	 	B&L Microscope — Stereo Zoom 6
	 	Broncus Cal. C0269
	 	 	1	 	 	$	1,500	 
	RF Generators

	 	RF Generators at Clinical sites
	 	 	 	 	14	 	 	$	72,800	 
	RF Generators

	 	RF Generator
	 	100302-012
	 	 	1	 	 	$	5,200	 
	RF Generators

	 	RF Generator
	 	033097-001
	 	 	1	 	 	$	5,200	 
	Camera Source

	 	Pentax Endovision 3000 MSV-00120-20
	 	 	 	 	1	 	 	 	 	 
	Camera Head

	 	Pentax
	 	07-333
	 	 	1	 	 	 	 	 
	Camera (goes with head above)

	 	Pentax
	 	6-0822
	 	 	1	 	 	 	 	 
	Pentax light source (old)

	 	Pentax LH-150A
	 	AA00400
	 	 	1	 	 	 	 	 
	LCD Projector

	 	Hitachi XGA / CP-X328T
	 	RT31001393
	 	 	1	 	 	$	2,000	 
	Polycom

	 	 	 	12775478
	 	 	1	 	 	$	500	 
	Polycom

	 	Lucent
	 	12259137
	 	 	1	 	 	$	300	 
	Fire Proof File Cabinet

	 	Schwab 1000
	 	 	 	 	1	 	 	$	1,200	 
	Supply cabinet (small)

	 	 	 	 	 	 	1	 	 	$	200	 
	Printer

	 	HP laser jet 4200dtn
	 	 	 	 	1	 	 	$	2,100	 
	Printer

	 	HP inkjet 1100
	 	 	 	 	1	 	 	$	325	 
	Postage meter (22 quarterly
payments of $112 start
12/03)

	 	Pitney Bowes Model E700
	 	 	 	 	1	 	 	$	2,400	 
	Postage scale

	 	Pitney Bowes Model N50R
	 	 	 	 	1	 	 	 	 	 
	Conference Room tables

	 	AVA 8’ x 4’
	 	 	 	 	3	 	 	$	2,000	 
	Servers

	 	Purchased from Baypoint Technology 11/03
	 	 	 	 	2	 	 	$	18,000	 

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Item	 	Model Number	 	Serial Number	 	QTY	 	Price
	KVM Switch

	 	 	 	 	 	 	1	 	 	$	250	 
	UPS Power Supplies

	 	 	 	 	 	 	2	 	 	$	1,050	 
	Cisco Router

	 	 	 	 	 	 	1	 	 	$	1,300	 
	Watchguard firewall

	 	 	 	 	 	 	1	 	 	$	1,050	 
	Cisco Switch

	 	 	 	 	 	 	1	 	 	$	575	 
	Phone System – Aspire

	 	includes 19 phones, vm,

main unit, door box, labor
	 	 	 	 	1	 	 	$	15,900	 
	Alarm Desktop computer

	 	Dell M200S
	 	 	 	 	1	 	 	$	500	 
	Refrigerator

	 	Kenmore
	 	 	 	 	1	 	 	$	600	 
	microwave

	 	 	 	 	 	 	1	 	 	$	90	 
	Toaster Oven

	 	 	 	 	 	 	1	 	 	 	 	 
	Kitchen tables

	 	Ikea
	 	 	 	 	4	 	 	 	 	 
	kitchen chairs

	 	Ikea
	 	 	 	 	20	 	 	 	 	 
	Conference room chairs

	 	Ikea
	 	 	 	 	12	 	 	 	 	 

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

Schedule 1.1(c)

Assigned Contracts

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Effective	 	Expiration
	Other Party to Contract	 	Legal Title of Contract	 	Description of Contract	 	Date	 	Date
	AT Cook Properties Trust1

	 	Standard Industrial/Commercial

Single-Tenant Lease
	 	Building Lease	 	 	 	 
	*****

	 	Subcontract Agreement between *****
and Broncus Technologies, Inc.
	 	Grant work
	 	9/30/2001
	 	8/31/2006
	*****

	 	Authorization to Proceed with:	 	 	 	 	 	 
	 

	 	Broncus (Protocol Number: 0602-20)
	 	Regulatory/Clinical
	 	6/9/2003	 	 
	*****

	 	Authorization to Proceed with:	 	 	 	 	 	 
	 

	 	Alair System for the Bronchial
Thermoplasty Treatment of Asthmat
	 	CRA training, etc.
	 	6/1/2003	 	 
	*****

	 	Confidential Disclosure Agreement
	 	clinical
	 	6/5/2003	 	 
	*****

	 	Contract Services Agreement
	 	technical writing
	 	8/21/2003
	 	8/31/2004
	*****

	 	Clinical Work and Services Agreement
	 	Denmark monitors
	 	10/17/2003	 	 
	*****

	 	License Agreement
	 	license agreement
	 	10/15/1998	 	 
	 
	 	 	 	 	 	 	 	 
	Independent Consultant 

Agreements
	 	 	 	 	 	 	 	 
	*****

	 	Independent Consultant Agreement
	 	reviews radiological

sections
	 	9/22/1998
	 	1/1/2001
	*****

	 	Independent Consultant Agreement
	 	R&D
	 	12/1/2003
	 	1/15/2004
	*****

	 	Independent Consultant Agreement
	 	DSMB (ex member)
	 	10/23/2001
	 	10/23/2002
	*****

	 	Independent Consultant Agreement
	 	R&D (works at JHU)
	 	10/22/1999
	 	10/31/2000
	*****

	 	Independent Consultant Agreement
	 	Clinical
	 	4/5/1999
	 	1/1/2002
	*****

	 	Independent Consultant Agreement
	 	DSMB
	 	9/18/2002
	 	9/18/2003
	*****

	 	Independent Consultant Agreement
	 	Non/Standard Cons. Agree.
	 	11/14/1998	 	 
	*****

	 	Independent Consultant Agreement
	 	Clinical trial help/*****
	 	6/6/2001	 	 
	*****

	 	Independent Consultant Agreement
	 	Dr. at Clinical site
	 	7/16/2003
	 	12/31/2008
	*****

	 	Independent Consultant Agreement
	 	regulatory & clinical
	 	4/12/2001
	 	12/31/2002
	*****

	 	Independent Consultant Agreement
	 	Clinical / Beth Israel

Deaconess Medical Center
	 	12/21/2001
	 	12/31/2006
	*****

	 	Independent Consultant Agreement
	 	Regulatory consulting
	 	8/1/2003
	 	8/1/2008
	*****

	 	Independent Consultant Agreement
	 	Clinical & Regulatory
	 	9/29/1997
	 	1/1/2000
	*****

	 	Independent Consultant Agreement
	 	Clinical & Regulatory,

Advisor, protocol Design

Issues
	 	7/9/2002
	 	12/31/2007
	*****

	 	Independent Consultant Agreement
	 	Biostatistics consult.
	 	2/1/2002
	 	2/1/2005

 

			
	1	 	Asthmatx and Broncus agree (i) that
Broncus’ lease with AT Cook Properties Trust shall not be assigned to
Asthmatx unless and until any consent of AT Cook Properties Trust necessary for
such assignment has been obtained, and (ii) if any such consent is necessary
and cannot be obtained, that Broncus shall attempt to sublet the premises
covered by such lease to Asthmatx.
	 
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Effective	 	Expiration
	Other Party to Contract	 	Legal Title of Contract	 	Description of Contract	 	Date	 	Date
	*****

	 	Independent Consultant Agreement
	 	supports clinical sites
	 	10/9/2001
	 	12/31/2002
	*****

	 	Independent Consultant Agreement
	 	Clinical & Regulatory
	 	6/24/2002
	 	12/31/2007
	*****

	 	Independent Consultant Agreement
	 	Clinical & Regulatory
	 	1/10/2003
	 	3/31/2004
	*****

	 	Independent Consultant Agreement
	 	R&D (Dr. at JHU)
	 	10/22/1999
	 	10/31/2000
	*****

	 	Independent Consultant Agreement
	 	Designer for letterhead,

etc
	 	2/8/2002	 	 
	*****

	 	Independent Consultant Agreement
	 	R&D, Clinical & Regul.
	 	11/3/1999
	 	12/31/2004
	*****

	 	Independent Consultant Agreement
	 	Research
	 	2/26/2002
	 	12/31/2002
	*****

	 	Independent Consultant Agreement
	 	R&D design & fabrication
	 	12/10/1997	 	 
	*****

	 	Independent Consultant Agreement
	 	Regulatory
	 	10/13/2000
	 	10/13/2001
	*****

	 	Independent Consultant Agreement
	 	Clinical help
	 	12/13/2001
	 	12/31/2004
	*****

	 	Independent Consultant Agreement
	 	DSMB
	 	8/15/2003
	 	8/15/2005
	*****

	 	Independent Consultant Agreement
	 	Regulatory
	 	10/11/2001	 	 
	*****

	 	Independent Consultant Agreement
	 	DSMB
	 	8/20/2003
	 	8/20/2005
	*****

	 	Independent Consultant Agreement
	 	QOL surveys for Clinical
	 	8/7/2002
	 	8/7/2005
	 
	 	 	 	 	 	 	 	 
	Nondisclosure Agreements
	 	 	 	 	 	 	 	 
	*****

	 	Nondisclosure Agreement
	 	Non Disclosure
	 	6/19/2000
	 	6/19/2005
	*****

	 	Nondisclosure Agreement
	 	Non Disclosure
	 	3/21/2001
	 	3/21/2006
	*****

	 	Nondisclosure Agreement
	 	Non Disclosure
	 	1/27/2003
	 	1/27/2008
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	9/15/2003
	 	9/15/2008
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	4/10/2003
	 	4/10/2008
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	2/17/2000
	 	2/17/2005
	*****

	 	Nondisclosure Agreement
	 	Marketing Vendor-nondisc.
	 	8/6/2001
	 	8/6/2006
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	4/17/1998
	 	4/17/2000
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	10/13/2000
	 	10/13/2005
	*****

	 	Nondisclosure Agreement
	 	NonDisclosure
	 	5/8/1998
	 	5/8/2000
	*****

	 	Nondisclosure Agreement
	 	Quality Assurance, *****
	 	7/6/01
	 	7/6/06
	*****

	 	Mutual Nondisclosure Agreement
	 	Vendor for Clinical

kits, *****
	 	8/8/2002	 	 
	*****

	 	Nondisclosure Agreement
	 	CFD Research
	 	1/27/03
	 	1/27/08
	*****

	 	Nondisclosure Agreement
	 	*****
	 	10/24/2003
	 	10/24/2008
	*****

	 	Nondisclosure Agreement
	 	Potential investigator
in Holland, Leiden Univ.
Medical Center
	 	3/13/2000
	 	3/13/2005
	*****

	 	Nondisclosure Agreement
	 	*****
	 	7/12/2002
	 	7/12/2007
	*****

	 	Nondisclosure Agreement
	 	*****
	 	11/18/2003	 	 
	 
	 	 	 	 	 	 	 	 
	Clinical Trial Contracts
	 	 	 	 	 	 	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	5/9/2003	 	 

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Effective	 	Expiration
	Other Party to Contract	 	Legal Title of Contract	 	Description of Contract	 	Date	 	Date
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	8/8/2003	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	8/12/2003	 	 
	*****

	 	Clinical Trial Agreement
	 	Portocol 0602-20
	 	9/17/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	 	 	1/22/2003	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	8/14/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	2/5/2003	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	11/21/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	12/1/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	8/22/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 0602-20
	 	12/20/2002	 	 
	*****

	 	Clinical Trial Agreement
	 	Protocol 1100-08
	 	1/15/2001	 	 

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

Schedule 1.1(d)

Assigned Patents Rights

Active Applications

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Application	 	 	 	Patent	 	 
	Docket Number	 	Country	 	Number	 	Application Date	 	Number	 	Title
	43571-20001.00

	 	United States
	 	 	08/833,550	 	 	4/7/1997
	 	 	6,273,907 B1	 	 	BRONCHIAL STENTER\n
	43571-20001.01

	 	United States
	 	 	10/232,909	 	 	8/30/2002
	 	 	 	 	 	METHOD OF INCREASING GAS EXCHANGE OF A LUNG\n
	43571-20001.10

	 	United States
	 	 	09/176,899	 	 	10/22/1998
	 	 	6,299,633 B1	 	 	BRONCHIAL STENTER\n
	43571-20001.11

	 	United States
	 	 	09/280,672	 	 	3/29/1999
	 	 	6,283,989 B1	 	 	METHOD OF TREATING A
BRONCHIAL TUBE WITH A
BRONCHIAL\nSTENTER HAVING
DIAMETRICALLY ADJUSTABLE
ELECTR
	*****

	 	*****
	 	 	*****	 	 	*****
	 	 	 	 	 	*****
	43571-20001.20

	 	United States
	 	 	08/994,064	 	 	12/19/1997
	 	 	6,083,255	 	 	BRONCHIAL STENTER\n
	43571-20001.21

	 	United States
	 	 	09/003,750	 	 	1/7/1998
	 	 	5,972,026	 	 	BRONCHIAL STENTER HAVING
DIAMETRICALLY ADJUSTABLE
ELECTRODES\n
	43571-20001.22

	 	United States
	 	 	09/224,937	 	 	12/31/1998
	 	 	6,200,333 B1	 	 	BRONCHIAL STENTER\n
	43571-20001.23

	 	United States
	 	 	09/260,401	 	 	3/1/1999
	 	 	6,283,988 B1	 	 	BRONCHIAL STENTER HAVING
EXPANDABLE ELECTRODES\n
	*****

	 	*****
	 	 	 	 	 	 	 	 	 	 	 	*****
	43571-20001.25

	 	United States
	 	 	09/349,715	 	 	7/8/1999
	 	 	6,488,673 B1	 	 	METHOD OF INCREASING GAS
EXCHANGE OF A LUNG\n
	43571-20001.45

	 	Australia
	 	 	33903/00	 	 	3/1/2000
	 	 	 	 	 	BRONCHIAL STENTER HAVING
EXPANDABLE ELECTRODES\n
	43571-20001.46

	 	Canada
	 	 	2362782	 	 	3/1/2000
	 	 	 	 	 	BRONCHIAL STENTER HAVING
EXPANDABLE ELECTRODES\n
	43571-20001.47

	 	European Patent

Convention
	 	 	9121211	 	 	3/1/2000
	 	 	1164958	 	 	BRONCHIAL STENTER HAVING
EXPANDABLE ELECTRODES\n
	43571-20001.48

	 	Japan
	 	 	2000601983	 	 	3/1/2000
	 	 	 	 	 	BRONCHIAL STENTER HAVING
EXPANDABLE ELECTRODES\n
	43571-20009.00

	 	United States
	 	 	09/095,323	 	 	6/10/1998
	 	 	 	 	 	METHOD AND MEANS FOR
TREATMENT OF PULMONARY
MUSCLES\n
	43571-20009.01

	 	United States
	 	 	10/414,253	 	 	4/14/2003
	 	 	 	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY
	43571-20009.02

	 	United States
	 	 	10/414,411	 	 	4/14/2003
	 	 	 	 	 	CONTROL SYSTEM AND
PROCESS FOR APPLICATION OF
ENERGY TO AIRWAY WALLS AND
OTHER MEDIUMS
	43571-20009.20

	 	United States
	 	 	09/296,040	 	 	4/21/1999
	 	 	6,411,852	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY\n
	43571-20009.21

	 	United States
	 	 	09/436,455	 	 	11/8/1999
	 	 	 	 	 	DEVICES FOR MODIFICATION
OF AIRWAYS BY TRANSFER OF
ENERGY\n
	43571-20009.22

	 	United States
	 	 	09/535,856	 	 	3/27/2000
	 	 	6,634,363	 	 	METHODS OF TREATING LUNGS
HAVING REVERSIBLE OBSTRUCTIVE
PULMONARY DISEASE
	43571-20009.23

	 	United States
	 	 	09/999,851	 	 	10/25/2001
	 	 	 	 	 	METHOD FOR TREATING AN
ASTHMA ATTACK\n
	43571-20009.44

	 	Japan
	 	 	2000553172	 	 	6/9/1999
	 	 	 	 	 	SMOOTH MUSCLE TREATMENT
APPARATUS AND TREATMENT\n
	43571-20009.47

	 	Australia
	 	 	4800700	 	 	4/21/2000
	 	 	 	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY\n

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Application	 	 	 	Patent	 	 
	Docket Number	 	Country	 	Number	 	Application Date	 	Number	 	Title
	43571-20009.48

	 	Canada
	 	 	2370223	 	 	4/21/2000
	 	 	 	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY\n
	43571-20009.49

	 	Japan
	 	 	2000611838	 	 	4/21/2000
	 	 	 	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY\n
	43571-20009.50

	 	European Patent

Convention
	 	 	9301318	 	 	4/21/2000
	 	 	 	 	 	MODIFICATION OF AIRWAYS
BY APPLICATION OF ENERGY\n
	*****

	 	*****
	 	 	*****	 	 	*****
	 	 	 	 	 	*****
	43571-20009.52

	 	Canada
	 	 	2,400,276	 	 	9/19/2002
	 	 	 	 	 	METHOD FOR TREATING AN
ASTHMA ATTACK\n
	*****

	 	*****
	 	 	*****	 	 	*****
	 	 	 	 	 	*****
	43571-20009.54

	 	Canada
	 	 	2,426,167	 	 	10/17/2001
	 	 	 	 	 	CONTROL SYSTEM AND
PROCESS FOR APPLICATION OF
ENERGY TO AIRWAY WALLS AND
OTHER\nMEDIUMS\n
	43571-20009.55

	 	Japan
	 	 	2002-535572	 	 	10/17/2001
	 	 	 	 	 	CONTROL SYSTEM AND
PROCESS FOR APPLICATION OF
ENERGY TO AIRWAY WALLS AND
OTHER\nMEDIUMS\n
	43571-20009.56

	 	European Patent

Convention
	 	 	1979858.6	 	 	10/17/2001
	 	 	 	 	 	CONTROL SYSTEM AND
PROCESS FOR APPLICATION OF
ENERGY TO AIRWAY WALLS AND
OTHER\nMEDIUMS\n
	*****

	 	*****
	 	 	*****	 	 	*****
	 	 	 	 	 	*****
	43571-20009.58

	 	Canada
	 	 	2,426,144	 	 	10/17/2000
	 	 	 	 	 	METHOD AND MEANS FOR
TREATMENT OF PULMONARY
MUSCLES\n
	43571-20009.59

	 	European Patent

Convention
	 	 	973613.3	 	 	10/17/2000
	 	 	 	 	 	METHOD AND MEANS FOR
TREATMENT OF PULMONARY
MUSCLES\n
	43571-20009.60

	 	Hong Kong
	 	 	3105480.3	 	 	7/3/2003
	 	 	 	 	 	CONTROL SYSTEM AND
PROCESS FOR APPLICATION OF
ENERGY TO AIRWAY WALLS AND
OTHER\nMEDIUMS\n
	A-004-001

	 	United States
	 	 	10/640,967	 	 	8/13/2003
	 	 	 	 	 	METHODS OF TREATING ASTHMA

Inactive Applications

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Application	 	 	 	 	 	 
	Docket Number	 	Country	 	Number	 	Application Date	 	Patent Number	 	Title
	43571-20001.40

	 	Patent Cooperation

Treaty
	 	PCT/US98/03759
	 	2/27/1998
	 	 	 	BRONCHIAL
STENTER TO PREVENT
AIRWAY COLLAPSE\n
	43571-20001.41

	 	Patent Cooperation

Treaty
	 	PCT/US99/00232
	 	1/7/1999
	 	 	 	BRONCHIAL
STENTER TO PREVENT
AIRWAY COLLAPSE\n
	43571-20001.42

	 	Patent Cooperation

Treaty
	 	PCT/US98/26227
	 	12/21/1998
	 	 	 	BRONCHIAL
STENTER TO PREVENT
AIRWAY COLLAPSE\n
	43571-20001.43

	 	Patent Cooperation

Treaty
	 	PCT/US00/05412
	 	3/1/2000
	 	 	 	BRONCHIAL
STENTER HAVING
EXPANDABLE
ELECTRODES\n
	43571-20001.44

	 	Patent Cooperation

Treaty
	 	PCT/US00/18197
	 	6/30/2000
	 	 	 	METHOD OF
INCREASING GAS
EXCHANGE OF A
LUNG\n
	43571-20009.40

	 	Patent Cooperation

Treaty
	 	PCT/US99/12986
	 	6/9/1999
	 	 	 	METHOD AND
APPARATUS FOR
TREATING SMOOTH
MUSCLES IN THE
WALLS OF BODY
CONDUITS\n
	43571-20009.41

	 	Patent Cooperation

Treaty
	 	PCT/US00/10847
	 	4/21/2000
	 	 	 	MODIFICATION OF
AIRWAYS BY
APPLICATION OF
ENERGY\n
	43571-20009.42

	 	Patent Cooperation

Treaty
	 	PCT/US00/28745
	 	10/17/2000
	 	 	 	METHOD AND
MEANS FOR TREATMENT
OF PULMONARY
MUSCLES\n
	43571-20009.43

	 	Australia
	 	PCT/US99/12986
	 	6/9/1999
	 	 	 	METHOD AND
APPARATUS FOR
TREATING SMOOTH
MUSCLES IN THE
WALLS OF BODY
CONDUITS\n

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Application	 	 	 	 	 	 
	Docket Number	 	Country	 	Number	 	Application Date	 	Patent Number	 	Title
	43571-20009.45

	 	European Patent

Convention
	 	PCT/US99/12986
	 	6/9/1999
	 	 	 	METHOD AND
APPARATUS FOR
TREATING SMOOTH
MUSCLES IN THE
WALLS OF BODY
CONDUITS\n
	43571-20009.46

	 	Patent Cooperation

Treaty
	 	PCT/US01/32321
	 	10/17/2001
	 	 	 	CONTROL SYSTEM
AND PROCESS FOR
APPLICATION OF
ENERGY TO AIRWAY
WALLS AND
OTHER\nMEDIUMS\n

 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

Schedule 1.1(e)

Assigned Trademark Rights

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	App.	 	 	 	 	 	 	 	 
	Mark	 	Country	 	Number	 	App. Date	 	Reg. Number	 	Reg. Date	 	Status
	ALAIR

	 	Canada
	 	1,061,603
	 	6/2/2000
	 	 	 	 	 	Pending
	ALAIR

	 	European Union
	 	1,687,680
	 	6/2/2000
	 	1,687,680
	 	7/18/2001
	 	Registered
	ALAIR

	 	United States
	 	75/863,338
	 	12/3/1999
	 	 	 	 	 	Pending
	ASTHMATX

	 	United States
	 	78/309,332
	 	10/3/03
	 	 	 	 	 	Pending
	The Asthmatx Logo

	 	United States
	 	78/325,822
	 	11/10/03
	 	 	 	 	 	Pending

 
 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

Schedule 1.2(c)

Exceptions to Term of Grant of Asthmatx Options to Broncus Optionees

Notwithstanding
Section 1.2(c), for any Broncus Optionee who is a
member of the board of directors of Asthmatx, and Sanjay Bagade, Charles Lombard, John Miller and
Andrew Newman (collectively, “Continuing Broncus Optionees”), (A) the provisions of Section
1.2(c)(i) (regarding the number of Asthmatx Options to be granted) shall not apply, and instead
such Continuing Broncus Optionee shall be granted, with respect to each of his Broncus Options, an
Asthmatx Option to purchase a number of shares of Asthmatx Common Stock equal to the total number
of shares of Broncus Common Stock subject to his Broncus Option (computed before the effect of any
modification or adjustment of such Broncus Option made in connection with the Spin-off); and (B)
each Asthmatx Option granted to such Continuing Broncus Optionee (1) shall be vested on the date it
is granted to the same extent that the Broncus Option with respect to which it was granted was
vested on such date, and (2) shall vest and become exercisable on the same terms and vesting
schedule as such Broncus Option, except that, for purposes of vesting, all applicable references to
Broncus in the Broncus Option shall be references to Asthmatx in such Asthmatx Option.

 
 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

 

 

Schedule 1.2(d)

Exceptions to Term of Grant of Asthmatx Options to Transferring Optionees

None.

 
 

			
	*****	 	Certain portions of this exhibit have been omitted and confidential treatment has been
requested for these omitted portions pursuant to an application for confidential treatment sent to
the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]